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Targeted next generation sequencing as a
tool for precision medicine
Markus Gulilat1,2, Tyler Lamb2, Wendy A. Teft1, Jian Wang3, Jacqueline S. Dron3, John F. Robinson3,
Rommel G. Tirona1,2, Robert A. Hegele3, Richard B. Kim1,2 and Ute I. Schwarz1*

Abstract
Background: Targeted next-generation sequencing (NGS) enables rapid identification of common and rare
genetic variation. The detection of variants contributing to therapeutic drug response or adverse effects is
essential for implementation of individualized pharmacotherapy. Successful application of short-read based
NGS to pharmacogenes with high sequence homology, nearby pseudogenes and complex structure has been
previously shown despite anticipated technical challenges. However, little is known regarding the utility of
such panels to detect copy number variation (CNV) in the highly polymorphic cytochrome P450 (CYP) 2D6
gene, or to identify the promoter (TA)7 TAA repeat polymorphism UDP glucuronosyltransferase (UGT) 1A1*28.
Here we developed and validated PGxSeq, a targeted exome panel for pharmacogenes pertinent to drug
disposition and/or response.
Methods: A panel of capture probes was generated to assess 422 kb of total coding region in 100 pharmacogenes.
NGS was carried out in 235 subjects, and sequencing performance and accuracy of variant discovery validated in
clinically relevant pharmacogenes. CYP2D6 CNV was determined using the bioinformatics tool CNV caller (VarSeq).
Identified SNVs were assessed in terms of population allele frequency and predicted functional effects through in silico
algorithms.
Results: Adequate performance of the PGxSeq panel was demonstrated with a depth-of-coverage (DOC) ≥ 20×
for at least 94% of the target sequence. We showed accurate detection of 39 clinically relevant gene variants
compared to standard genotyping techniques (99.9% concordance), including CYP2D6 CNV and UGT1A1*28.
Allele frequency of rare or novel variants and predicted function in 235 subjects mirrored findings from large
genomic datasets. A large proportion of patients (78%, 183 out of 235) were identified as homozygous
carriers of at least one variant necessitating altered pharmacotherapy.
Conclusions: PGxSeq can serve as a comprehensive, rapid, and reliable approach for the detection of
common and novel SNVs in pharmacogenes benefiting the emerging field of precision medicine.
Keywords: Targeted exome sequencing, Next generation sequencing, Pharmacogenes, Copy number variation,
In silico prediction
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Background
Rapid identification of genetic variation contributing to
therapeutic drug response or adverse effects is essential for
implementation of individualized pharmacotherapy [1].
Many gene-drug associations are now recognized as clinically relevant, particularly those involving genes encoding
drug metabolizing enzymes, membrane transporters, and
certain drug targets, which together are often referred to as
pharmacogenes [2]. Clinical guidelines have been developed
for drugs with the strongest level of evidence of utility for
pharmacogenetic testing in patients. For instance, the Clinical Pharmacogenetics Implementation Consortium (CPIC),
an international expert group, documents the available evidence and provides recommendations for clinicians on
genotype-based drug therapy [3]. CPIC guidelines have now
been reported for more than 35 drugs including the anticoagulant warfarin [4, 5], the antiplatelet agent clopidogrel
[6, 7], the cholesterol- lowering medication simvastatin [8],
chemotherapeutics such as thiopurines (azathioprine and
mercaptopurine) [9, 10], tamoxifen [11], and fluoropyrimidines [12], as well as the antiretroviral therapeutics abacavir
[13] and atazanavir [14]. As well, many pharmacogenetic
biomarkers have been incorporated in drug labels by the US
Food and Drug Administration [15] and the European Medicines Agency [16].
Earlier research evaluated common functional variation in pharmacogenes, while more recent large-scale
whole genome or exome sequencing studies revealed
that humans harbor a large number of rare, potentially
deleterious variants in many of the same genes [17–20].
Specifically, the analysis of sequencing data for 146 pharmacogenes combining about 7500 individuals of the Exome Sequencing Project (ESP) [21] and the 1000
Genomes Project (1000G) [22] indicated that more than
90% of all recorded single nucleotide variants (SNVs)
were rare with a minor allele frequency (MAF) below
1%, and that 30–40% of the predicted functional variability was associated with these rare variants [17]. Recent
studies also support that rare SNVs in drug processing
or drug target genes significantly contribute to interpatient differences in drug disposition and response beyond
established common genetic predictors as shown for
cytochrome P450 (CYP) 2C9 and warfarin dose requirement [23, 24] and solute carrier organic anion transporter (SLCO) 1B1 and methotrexate clearance and
toxicity [25].
Next-generation sequencing (NGS) refers to rapid,
high-throughput technologies that enable massively parallel DNA sequencing of entire human genomes, exomes or
coding exons of select genes [26]. Targeted exome NGS
capture panels are gaining popularity for pharmacogenetic
testing due to their time- and cost-effectiveness, and ability to simultaneously detect common and rare genetic
variation [27, 28]. Despite anticipated technical challenges
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for the application of short-read based NGS to genes with
high sequence homology, nearby pseudogenes and complex structure [29–31], these limitations might be overcome through careful probe design (i.e. target enrichment
[32]) combined with advanced bioinformatics approaches
as suggested by previous reports [27, 28, 33]. However, little is currently known regarding the utility of such panels
to detect copy number variation (CNV) in the highly polymorphic CYP2D6 gene, or to identify the promoter (TA)7
TAA repeat polymorphism UDP glucuronosyl-transferase
(UGT) 1A1*28, two common polymorphisms known to
affect enzymatic activity and alter dose requirements for
substrate drugs [34, 35]. Therefore, we created a
NGS-based exome capture panel (PGxSeq) capable of detecting clinically established as well as novel genetic variation with potential implications in drug disposition and
response. We applied our PGxSeq panel to 1) evaluate the
sequencing performance achieved with the utilized targetenrichment strategy, 2) determine the accuracy of variant
discovery in clinically relevant pharmacogenes compared to
traditional genotyping methods including CYP2D6 CNV
and UGT1A1*28, and 3) evaluate the identified variation
with respect to population allele frequencies and predicted
functional effects.

Methods
Sample collection

Genomic DNA (gDNA) was obtained from venous blood
samples of 246 Caucasian subjects (220 adult and 26
pediatric patients) following written informed consent.
Studies were approved by the Research Ethics Board of
Western University, London, Canada. A flow diagram of
the sample and subsequent data processing can be found
in Fig. 1.
Gene selection, capture probe design and enrichment
method

We used the Nextera Rapid Capture Custom Enrichment
Kit (Illumina, San Diego, CA) for the enrichment of coding regions of 100 genes encoding major cytochrome
P450 (CYP) enzymes, phase II conjugation enzymes, drug
transporters of the solute carrier (SLC) and ATP binding
cassette (ABC) families as well as regulatory proteins of
relevance to variability in drug ADME (absorption, distribution, metabolism, excretion) and response including regions encompassing 14 known functional promoter or
intronic SNVs such as UGT1A1*28, CYP3A5*3, and
CYP2D6*41 (Additional file 1: Table S1 and S2).
A total of 10,207 capture probes (80 bp) were customdesigned using the Illumina Design Studio (Illumina,
San Diego, CA) comprising 722 kilobases (kb) of sequence per sample (Genomic coordinates in Additional
file 1: Table S1). Exons of all coding isoforms were targeted
for selected genes including 300 bp intronic (flanking each
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Fig. 1 PGxSeq sample and data processing workflow (n = 246). Eleven subjects were excluded from variant analysis due to low read count (†; n =
1) and high GC content (‡; n = 10). All clip art depicted in this Figure has been created by the authors

exon) and 250 bp of 5′ and 3′ untranslated regions (UTR).
Known functional non-coding variants were separately targeted if not captured otherwise (Additional file 1: Table S2).
Chromosomal coordinates were obtained from University
of California Santa Cruz (UCSC) genome browser using the
GRCh37/hg19 human genome assembly. DNA library preparation and subsequent target-capture sequencing was conducted at the London Regional Genomics Center, London,
Ontario, as previously described [36]. Briefly, DNA samples
were processed in 13 runs in batches of 12 or 24 samples
(referred to as sequencing cluster). After serial dilutions,
DNA was adjusted to a final concentration of 5.0 ± 1 ng/μl
using the Qubit DNA kit (Invitrogen, Eugene, OR). DNA
was enzymatically fragmented, polymerase chain reaction
(PCR)-amplified with individual sample barcodes, equimolar
pooled, hybridized to the biotinylated capture probes,
pooled using streptavidin beads, and PCR-amplified again to
select the final target sequence. Resulting libraries were
quantified, and loaded on to a standard flow-cell on the Illumina MiSeq Sequencer (Illumina, San Diego, CA) using 2 ×
300 bp or 2 × 150 bp paired-end chemistry.

Base calling, sequence alignment and variant detection

Prior to the alignment of reads to the reference genome,
sequencing performance metrics were assessed (Fig. 1).
Paired-end sequenced reads were separated according to
sample-specific barcodes and sequencing data downloaded as FASTQ files that were further assessed with the
quality control tool, FastQC [37], including read count,
base quality across reads (also Phred score, Q; describes
the probability of a sequencing error as a measure of base

call accuracy), and guanine and cytosine (GC) content per
sequence [38].
Alignment of sequencing reads and variant calling were
performed using the CLC Bio Genomics Workbench 9.0
(CLC Bio, Aarhus, Denmark) through a custom automated workflow. FASTQ files were imported and mapped
to the reference human genome (GRCh37/hg19 build).
Using default algorithms (i.e. Local Realignment and Remove Duplicate Mapped Reads), initial read mapping was
further optimized around insertion-deletion mutations
(indels) and PCR duplicates removed.
Depth-of-coverage (DOC; also coverage) was defined
as the number of reads mapped to a genomic position
following alignment of sequenced reads and removal of
duplicate reads. Reads that were non-specific matches
(mapped to more than one location of hg19 reference
genome) or missing the paired read were excluded from
this calculation. For every subject, a Coverage Summary
Report along with a base-by-base Coverage Table were
exported. Coverage analysis was restricted to coding regions including 10 bp before and after each exon, and
250 bp of 3′ and 5’UTR. To detect samples with substantial regions of low coverage, we expressed coverage
as percentage of the 422 kb target sequence with a DOC
≥1×, ≥ 10×, ≥ 20×, and ≥ 30× (Table 1). Subjects with
more than 20% of their target sequence below 10× were
excluded from variant analysis. Coverage was also
assessed at the gene level and by sequencing cluster (n =
12 or 24).
To further ensure accuracy of variant and genotype calling, quality-based variant detection tools were employed
with the following parameters: diploid organism, probability

Gulilat et al. BMC Medical Genomics

(2019) 12:81

Page 4 of 17

Table 1 PGxSeq performance by sequencing cluster
12-plex

24-plex

Subjects, n

52

183

Average reads (duplicates removed), per sample

1.01 M

0.54 M

DOC, mean (median)

213-fold ª (207-fold) ª

87.2-fold ª (84-fold) ª

Bases with mean DOC ≥1×, %

98.7 b

98.6 b

Bases with mean DOC ≥10×, %

98.0 b

96.8 b

Bases with mean DOC ≥20×, %

97.4

b

94.3 b

Bases with mean DOC ≥30×, %

96.8 b

90.9 b

DOC depth of coverage
ª Calculated across the 422 kb target sequence including all subjects each group
b
Represented as group mean for the percent base pairs (from 422 kb target sequence) with a DOC ≥1×, ≥ 10×, ≥ 20×, or ≥ 30 ×

of non-reference allele ≥95% (versus sequencing error), ≥
10-fold coverage (10×), ≥ 20% read frequency, and ≥ 30 per
base quality score at the variant location. Resulting sequence variation reports were exported in variant call format (VCF) for downstream annotation.
UGT1A1*28 carrier status was separately determined
by manually assessing the number of TA repeats in the
NGS sequence of individual reads mapped to the promoter region (n = 235). Each subject’s promoter region
was interpreted as the percentage of mapped reads with
six TA (TA)6 repeats, with subject values clustering into
three separate groups in a histogram (Fig. 4a). We evaluated concordance of UGT1A1*28 genotype determined
by NGS with a previously reported TaqMan assay [39] in
a subgroup of 81 subjects.
CYP2D6 whole gene CNV was determined from NGS
data using the bioinformatics tool CNV caller, an application within the VarSeq v1.3.4 variant annotation software
(Golden Helix, Bozeman, MT), as previously described by
Iacocca et al. [40]. VarSeq CNV caller identifies probable
CNV carriers through coverage analysis, by normalizing
the coverage across the CYP2D6 gene for samples of interest compared to a reference control group (2 gene copies).
CNV analysis was restricted to samples processed in the
24- sequencing cluster runs (n = 183) to minimize confounding of sample preparation on coverage. First, we determined the CYP2D6 CNV status in 48 samples using a
TaqMan CNV assay (Hs04502391_cn), from which 30
subjects with 2 CYP2D6 copies were selected for our reference control group. CNV status for the remaining subjects was then determined using this reference group.
Only subjects that were found to be positive for a CNV
(deletion or duplication) were further confirmed among
the remaining 135 subjects using the TaqMan CNV assay.
Variant annotation and in silico functional assessment

Functional annotation of SNVs was carried out using
ANNOVAR [41] through in silico prediction algorithms
such as Combined Annotation Dependent Depletion
(CADD) [42], Sorting Intolerant from Tolerant (SIFT)

[43], and PolyPhen-2 [44], and variant frequency among
different populations was determined utilizing large genomic databases (Reference Sequence [RefSeq], Single Nucleotide Polymorphism database build 150 [dbSNP150],
1000 Genomes, Exome Aggregation Consortium [ExAC])
obtained October 17, 2018. SNVs with a CADD Phred
score (scaled) greater than 20 [42], a SIFT score of less
than 0.05 [43], or a PolyPhen-2 score of greater than 0.85
[44] were considered as potentially functional variants (altering protein function), and herein defined as deleterious.
Variants were classified as 1) non-synonymous (coding
variants resulting in amino acid change), 2) synonymous
(coding variants without amino acid changes), 3) frameshift deletion or insertion (in-del), 4) splicing (2 nucleotides within an intron-exon boundary), 5) stop gain or loss,
or 6) functional intronic or promoter variants. Coding variants were further grouped by MAF reported in the ExAC
database as common (MAF ≥ 5%), low frequency (1% ≤
MAF > 5%), or the combined category of rare (MAF < 1%)
and novel (absent from ExAC and dbSNP build 150 databases). In silico functional assessment was restricted to
protein-coding genetic variation and gain or loss of a stop
codon.
Concordance assessment

To assess concordance of clinically actionable NGS variant
data, orthogonal genotyping was performed using TaqMan
allelic discrimination for 39 clinically relevant SNVs including UGT1A1*28 and CYP2D6 CNV. SNVs were chosen according to the level of evidence as defined by the
Pharmacogenomics Knowledge Base or PharmGKB (http://
www.pharmgkb.org/clinicalAnnotations accessed October
17, 2018) including 21 Level 1A SNVs with published
prescribing recommendations for genotype-based dose
adjustment or drug avoidance. Rare NGS variants were
confirmed retrospectively by Sanger sequencing within 4
highly polymorphic pharmacogenes, namely ABCB1,
CYP2D6, SLCO1B1, and SLCO1B3. PCR conditions and sequencing primers as well as TaqMan assay IDs are listed in
Additional file 1: Table S3 and Table S4, respectively.
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Results
Sequencing performance

Prior to alignment to the reference genome, sequencing
data for all 246 subjects was assessed for read count, base
quality, and GC distribution (Fig. 1 and Additional file 2:
Figures S1-S3). The total number of sequenced reads per
subject was dependent on sequencing cluster size, and one
subject was identified to have very low read count (< 1 k
reads) (Additional file 2: Figure S1). The majority of reads
showed an average base quality score above 30 (Phred
scale) among the 13 sequencing runs performed
(Additional file 2: Figure S2). The average GC content of
reads (per subject) was 45.6 ± 2.0% (mean ± SD). GC content distribution deviated greatly in 9 subjects compared to
the remaining cohort (Additional file 2: Figure S3). After
alignment of reads to the reference genome, we assessed
coverage across the target sequence, and identified 11 subjects with greater than 20% of their target sequence ≤10×
read depth, including those with high GC content. Overall,
we observed a negative correlation between the low coverage and high GC content (Additional file 2: Figure S3 B). In
order to avoid false negative variant calling as previously reported [38], 11 subjects with low reads and/or high GC
content were removed from further analysis.
Accordingly, NGS data of 235 subjects were included
for subsequent coverage analysis, and assessed by sequencing cluster (n = 12 or 24) (Table 1). As expected,
samples in the smaller cluster had a greater mean DOC
per subject compared to those sequenced in the larger
24 DNA sample cluster (Table 1). Overall, the proportion of bases with a read depth ≤ 10× was very small (2–
3.2%). On a gene-by-gene basis, on average, 98 of the
100 genes on our panel had a median DOC ≥50×, with
≥80% of the target region within these genes having
DOC ≥30× representing deep sequencing (Fig. 2). We
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observed overall high coverage across clinically relevant
pharmacogenes including regions of PharmGKB Level
1A/1B variants (http://www.pharmgkb.org/clinicalAnnotations) (Fig. 3). Among all genes, the glutathione
S-transferase (GST) M1 gene showed the lowest coverage per subject and large intersubject variability (minmax; 0–310×). For carboxylesterase 1 (CES1), there was
lack of coverage for exons 12 to 14, resulting in a high
proportion of targeted regions < 30×, followed by carbonyl reductase 3 (CBR3) (Additional file 2: Figure S4).
Accuracy of variant detection

Genotyping with TaqMan assays was utilized to validate 39
clinically relevant variants across 215 subjects (9 variants
per subject, on average) detected with NGS data (Table 2).
We observed 99.9% concordance between NGS-derived
and TaqMan-derived genotypes confirming heterozygous
and homozygous carrier status. While we did not detect
any false positive results (a variant was detected by NGS
but not confirmed by TaqMan genotyping; specificity of
100%, 95% CI, 100–100%), a false negative NGS result was
observed in two heterozygous carriers for DPYD
rs67376798 and CYP2D6*10 rs1065852 (no variant detected by NGS but observed by TaqMan genotyping; sensitivity of 99.7%, 95% CI, 99.2–100%). However, subsequent
assessment of individual reads revealed a variant in both
subjects that was previously not called due to the low
coverage in the SNV region, since the threshold for
variant detection was not met (DOC ≥10x). Using
Sanger sequencing, we were able to retrospectively
confirm five rare coding variants that were identified by
NGS in ABCB1, CYP2D6, SLCO1B1, and SLCO1B3
(Additional file 1: Table S5).
UGT1A1*28 polymorphism detection using NGS data
was carried out manually in 235 individuals. Each subject’s

Fig. 2 Depth-of-coverage (DOC) assessment by gene according to size of sequence cluster (n = 12 or 24). † For UGT1A4, UGT1A6, UGT1A8, and
UGT1A9, the first exon was included to calculate DOC while shared exons were assessed only once with UGT1A1. Data are shown as average (±
SD) median gene coverage per subject
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Fig. 3 Depth-of-coverage (DOC) across the targeted sequence of 11 clinically relevant genes (n = 24; Sequencing Run 1 and 2). PharmGKB level
1A/1B variants (http://www.pharmgkb.org/clinicalAnnotations) are represented by rs number and genomic position by vertical lines (red). Data are
presented as mean (±SD). PharmGKB, Pharmacogenomics Knowledge Base
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Table 2 Concordance rate (%) between PGxSeq sequencing data compared to TaqMan-derived genotypes for clinically important
SNVs as defined by PharmGKB
PharmGKB Gene

Allele

Level of
evidence

Nucleotide
change

Effect

dbSNP
150

Allele frequency
Study

1000G

(n = 235) EUR

Concordanceª FP

ExAC

Patients genotyped (N) (%)

EUR

WT

HET

HOM

NR

23

11

1

25

(%) (%)

CYP2C19 *17

C>T

promoter rs12248560 0.23

1A

CYP2C19 *2

G>A

p.P227P

rs4244285

0.14

0.15

0.15

1A

CYP2C19 *3

G>A

p.Y212X

rs4986893

ND

0

1.80E-04 50

1A

CYP2C9

*2

C>T

p.R144C

rs1799853

0.13

0.12

0.13

72

23

3

100

0

0

1A

CYP2C9

*3

A>C

p.I359L

rs1057910

0.06

0.06

0.07

87

13

0

100

0

0

1A

CYP2D6

*10

C>T

p.P34P

rs1065852

0.21

0.2

0.25

30

19

3

98.1

0

1.9

1A

CYP2D6

*4

G>A

splice

rs3892097

0.19

0.19

0.17

52

26

6

100

0

0

1A

CYP2D6

*3A

A > del

p.R208fs

rs35742686 0.03

0.02

0.02

50

2

0

100

0

0

1A

CYP2D6

*41

G>A

intronic

rs28371725 0.12

0.09

0.09

38

14

0

100

0

0

1A

CYP3A5

*3

A>G

splice

rs776746

0.93

0.95

NR

1

9

27

100

0

0

1A

CYP4F2

*3

C>T

p.V433 M

rs2108622

0.30

0.27

0.29

23

17

0

100

0

0

1A

DPYD

*13

T>G

p.I560S

rs55886062 2.1E-03

1.3E-03

6.18E-04 97

1

0

100

0

0

1A

DPYD

*2A

G>A

splice

rs3918290

0.01

0.01

1

0

100

0

0

1A

DPYD

A>T

p.D949V

rs67376798 0.02

2.2E-03

4.09E-03 80

8

0

98.9

0

1.1

1A

SLCO1B1 *5

T>C

p.V174A

rs4149056

0.18

0.17

0.16

31

4

100

0

0

1A

TPMT

*2

G>C

p.A80P

rs1800462

2.1E-03

6.00E-03 1.97E-03 51

1

0

100

0

0

1A

TPMT

*3B

G>A

p.A154T

rs1800460

0.04

0.03

0.04

10

0

100

0

0

1A

TPMT

*4

G>A

splice

rs1800584

ND

NR

3.01E-05 51

0

0

100

0

NA

1A

TPMT

*3C

A>G

p.Y240C

rs1142345

0.04

0.03

0.04

41

10

0

100

0

0

*28

100

67

41

100

FN

1A

0.02

0.23

TaqMan

0

0

11

0

100

0

0

0

0

100

0

NA

1A

UGT1A1

1A

VKORC1

1B

CYP2B6

2A

ABCB1

2A

CYP2D6

AAG > del

p.K281del rs5030656

0.02

0.02

0.03

48

4

0

100

0

0

2A

SLCO1B1 *1B

A>G

p.N130D

rs2306283

0.41

0.40

0.41

40

46

15

100

0

0

2B

ABCG2

C>A

p.Q141K

rs2231142

0.12

0.10

0.10

87

20

1

100

0

0

3

ABCC2

G>A

p.V417I

rs2273697

0.19

0.20

0.20

45

19

4

100

0

0

3

ABCG2

G>A

p.V12 M

rs2231137

0.04

0.06

0.05

81

9

0

100

0

0

3

CYP2B6

C>T

p.R487C

rs3211371

0.12

0.10

0.12

23

8

0

100

0

0

3

CYP3A4

*22

C>T

intronic

rs35599367 0.05

0.05

NR

36

8

0

100

0

0

3

DPYD

HapB3 G > A

p.E412E

rs56038477 0.03

0.02

0.02

73

11

0

100

0

0

3

SLCO2B1

G>A

p.R290Q

rs12422149 0.06

0.10

0.11

62

6

0

100

0

0

*9

*9

(TA)6 > (TA)7 promoter rs3064744

0.32

0.29

NR

36

40

5

100

0

0

G>A

intergenic rs9923231

0.40

0.40

NR

19

15

6

100

0

0

G>T

p.Q172H

rs3745274

0.21

0.23

0.24

22

9

0

100

0

0

C>T

p.I1145I

rs1045642

0.48

0.47

0.47

18

61

26

100

0

0

ª Percentage of total tested DNA samples with NGS-determined genotypes concordant with TaqMan results. False positive was defined as TaqMan determined
“homozygous wildtype” and NGS determined “variant carrier”. False negative was defined as TaqMan determined “variant carrier” and NGS determined
“homozygous wildtype”. PharmGKB definition for levels of evidence can be found at https://www.pharmgkb.org/page/clinAnnLevels. Nucleotide change presented
as the change on the coding strand. Abbreviations: dbSNP 150 Single Nucleotide Polymorphism database build 150, ExAC Exome Aggregation Consortium
European dataset, FP false positive, FN false negative, HET heterozygous genotype, HOM homozygous genotype, ND not detected in our patient database, NA not
applicable as no variant carriers were found, NR, not reported in, 1000G EUR, or ExAC database, 1000G EUR 1000 Genomes Project European dataset, PharmGKB
Pharmacogenomics Knowledge Base

promoter region was expressed as the percentage of reads
with six TA repeats, which clustered into 3 separate groups
according to their frequency distribution (Fig. 4a), and
UGT1A1*28 genotype (*1/*1, *1/*28, *28/*28) confirmed by

TaqMan genotyping in a subset of 81 subjects (Fig. 4b;
Table 2).
CYP2D6 whole gene CNV analysis was performed in
all subjects processed in the 24 sample sequencing

Gulilat et al. BMC Medical Genomics

(2019) 12:81

Page 8 of 17

A

B

Fig. 4 Determination of UGT1A1*28 (TA)7 promoter repeat by next-generation sequencing (NGS). a Schematics of manual assessment of aligned
reads within the UGT1A1 promoter region, and multimodal frequency distribution pattern of UGT1A1*28 genotype. b Confirmation of NGS
determined UGT1A1*28 genotype by TaqMan assay
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A

B

Fig. 5 Next-generation sequencing (NGS)-based detection of CYP2D6 copy number variation. a Representative NGS output for a
duplication of the whole CYP2D6 gene (Subject PGAR1622 with CYP2D6*1/*1 genotype; refer to Table 2 for more detail). b Representative
NGS output for a heterozygous deletion of the whole CYP2D6 gene (Subject PGST217 with CYP2D6*1/*5 genotype; refer to Table 2 for
more detail). Different regions of the output are as follows: (i) Exon map of the CYP2D6 gene. (ii) PGxSeq probe target regions. (iii) Called
CNV state per probe target region, determined by ratio and z-score metrics. (iv) Normalized ratio metric computed for each NGS probe
target region in CYP2D6; sample coverage compared to reference controls (N = 30). (v) Z-score metric: number of standard deviations the
depth of coverage is from the reference control mean coverage
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cluster (n = 183). A representative sample output for a
subject with a CYP2D6 duplication and deletion is
shown in Fig. 5. We detected a gene deletion (heterozygous form) and duplication in 2.5 and 3.3% of subjects,
respectively, which were confirmed by TaqMan CNV
assay (Table 3). Notably, CYP2D6 genotype revealed duplications of *4 and/or *41 alleles in three out of 6 patients resulting in a predicted intermediate metabolizer
phenotype for CYP2D6. In addition, gene deletion occurred in combination with *3 and *4 alleles, resulting in
a predicted poor metabolizer status in four out of 9
patients.
Analysis of variants in pharmacogenes

Genetic variation was assessed in 235 Caucasian study
subjects (Additional file 1: Table S6), and SNVs presented
in Fig. 6 according to functional effect, number of variants
per gene, and reported MAF in ExAC (if exonic), the latter
capturing NGS exome data of 60,706 individuals [45]. A
total of 1093 unique SNVs were identified, consisting of
605 non-synonymous (55.4%), 417 synonymous (38.1%), 7
splice-site (0.6%), 14 stop gain or loss (1.4%), and 35
insertion-deletions (18 frameshift, 17 non-frameshift;
3.2%), as well as 15 known non-coding SNVs (1.4%) (Fig.
6a). The majority of variants (72%) were only present in
heterozygous form. Among exonic variants (Fig. 6b),
26.3% of SNVs were common (ExAC MAF > 5%), 14.2%
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occurred at a low frequency (ExAC MAF ≥1 and ≤ 5),
whereas 59.5% were either rare or novel (ExAC MAF < 1%
or absent from ExAC or dbSNP150). MAFs in this study
largely mirrored those reported in much larger data sets
of subjects with European descent (ExAC, 1000G)
(Additional file 2: Figure S5). According to gene family or
drug-related function, the CYP gene families had the most
variants per targeted base pairs, followed by the ABC and
UGT family, then SLC family, while nuclear receptors were
the least variable (Fig. 6c). Individually, among Phase I enzymes, CYP2D6 had the highest total number of exonic
SNVs (54) and the highest number of rare or novel variants from our gene panel (Fig. 6d), whereas UGT1A4 and
N-acetyltransferase 1 (NAT1) had the most SNVs among
Phase II enzymes. Within the SLC family, organic cation
transporter 1 (SLC22A1) showed the highest number of
SNVs as well as rare or novel SNVs among all SLC genes
sequenced. Among transporter genes of the ABC family,
ABCC2 had the highest number of the SNVs with 33 variants. No variants were detected for CYP3A7 and SLC51B,
despite adequate coverage achieved across both coding
sequences.
In silico assessment of variants in pharmacogenes

Potential functional effects of the identified non- synonymous variants were assessed with CADD, PolyPhen- 2, and
SIFT. Our results showed marked differences between the

Table 3 NGS-based detection of CYP2D6 whole gene copy number variation (CNV) in 183 subjects. For more detail on the
detection, refer to Fig. 5
Subject ID

CYP2D6 copy number detection
TaqMana

NGS

CYP2D6
genotype

Phenotype
prediction

Coverage
ratio

Z-score

Gene copy number

Ratio

Gene copy number

PGAR844

0.55

−3.16

1

0.44

1

*1/*5

IM

PGAR867

0.51

−3.36

1

0.44

1

*1/*5

IM

PGON198

0.50

−2.96

1

0.53

1

*4/*5

PM

PGST66

0.43

−3.54

1

0.45

1

*3/*5

PM

PGST140

0.48

−3.39

1

0.43

1

*1/*5

IM

PGST217

0.45

−3.55

1

0.45

1

*1/*5

IM

PGST52

0.54

−2.74

1

0.45

1

*1/*5

IM

PGAR1070

0.47

−3.33

1

0.48

1

*4/*5

PM

PGAR1132

0.46

−3.79

1

0.49

1

*4/*5

PM

PGAR1622

1.44

3.59

>2

1.40

>2

*1/*1

UM

PGON142

1.30

3.20

>2

1.48

>2

*1/*1

UM

PGON287

1.62

4.04

>2

1.90

>2

*41/*4

IM

PGST38

1.32

1.91

>2

1.38

>2

*1/*4

IM

PGON194

1.29

2.25

>2

1.98

>2

*1/*4

IM

PGST223

1.60

3.25

>2

1.86

>2

*1/*1

UM

PM poor metabolizer, IM intermediate metabolizer, UM ultrarapid metabolizer
a
Validation by TaqMan CNV assay in subjects that were identified with CNV (n = 15), and 48 subjects initially characterized to select a reference control
group (n = 30)
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(See figure on previous page.)
Fig. 6 Assessment of genetic variation determined by PGxSeq in 235 subjects. According to functional effect (a), allele frequency reported in
ExAC database (b), number of exonic variants per target region (c), and gene (d). ‡ For UGT1A4, UGT1A6, UGT1A8, and UGT1A9, only SNVs located
within the first exon were counted while shared exons were assessed only once with UGT1A1. ExAC, Exome Aggregation Consortium; MAF, minor
allele frequency

prediction scores derived from these algorithms (Fig. 7a).
However, the proportion of rare (MAF < 1%) or novel variants that were categorized as possibly deleterious was
greater than the proportion of common (≥ 5%) or low frequency (≥ 1–5%) variants for all 3 tools (CADD: p = 0.0002,
PolyPhen-2: p = < 0.0001, and SIFT: p = 0.0002) (Additional
file 2: Figure S6). The majority of pharmacogenes (96 out of
100) harbored at least one variant with a CADD score > 20

(median, 5) (Fig. 7b). On average, 14.8% (9.3–21.3%,
min-max) of the coding (exonic) variants detected across
the 100 pharmacogenes per subject were predicted as deleterious (CADD score > 20). Although the majority of these
variants were observed in heterozygous form (Additional
file 2: Figure S7), all 235 subjects had ≥1 deleterious variant(s) in the homozygous form, with a median of 4 (1–12,
min-max) SNVs per subject. Finally, we assessed prediction

A

B

Fig. 7 In silico assessment of non-synonymous variation in pharmacogenes identified by PGxSeq (N = 235). a Frequency distribution of
variants according to SIFT, PolyPhen-2, and CADD scores separated by minor allele frequency reported in the ExAC database. Shaded
regions represent the proportion of potentially functional variants (or deleterious), defined as a scaled CADD score > 20 [42], a SIFT
score < 0.05 [43], or a PolyPhen-2 score > 0.85 [44]. b Box and whisker plots of scaled CADD scores separated by gene; whiskers represent
10-90th percentile with purple symbol (■) representing the median. ABC, ATP binding cassette; CADD, Combined Annotation Dependent
Depletion; ExAC, Exome Aggregation Consortium; MAF, minor allele frequency; SIFT, Sorting Intolerant from Tolerant; SLC, solute carrier
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scores among 12 CYP genes that account for the majority
of reported drug oxidation reactions (Additional file 1:
Figure S8); on average, 11% of SNVs (10 - 90th percentile,
4.1–20.0%) with a CADD > 20 among individuals were
located within these genes.

Variation in genes of clinical relevance

Among 11 clinically relevant genes for which prescribing
guidelines for specific gene-drug combinations have been
published (cpicpgx.org/genes-drugs/), there are 31
PharmGKB Level 1A and 1B variants categorized as having strong evidence for influencing drug efficacy/response
and/or prescribing recommendations (Fig. 3). We identified 24 out of these 31 variants in our cohort, with 183 patients (78%) harbouring at least one PharmGKB level 1A/
1B homozygous variant (Additional file 2: Figure S9).

Discussion
As genotype-guided pharmacotherapies advance into the
clinical setting, targeted NGS technologies provide great
utility by simultaneously detecting common as well as rare
genetic variation of potential relevance to adverse or desired drug response in patients. In this study, we established
and validated a comprehensive targeted PGxSeq exome
panel for most clinically important pharmacogenetic loci.
Our findings demonstrate excellent concordance for the
detection of clinically relevant variants compared to standard pharmacogenetic assays including the UGT1A1*28 promoter (TA)7 TAA repeat and CYP2D6 copy number
variation. Moreover, adequate read depth along the target
regions and a strong correlation of allelic frequencies for
rare and novel variants in this population compared to larger genetic datasets suggests accurate and reliable results,
while confirming the high prevalence of such potentially
functional variation within pharmacogenes.
Compared to traditional genotyping or sequencing strategies, the applied targeted exome sequencing strategy
enabled accurate genotyping for common, previously established functional variation across exonic and intergenic regions in clinically important pharmacogenes as well as the
comprehensive discovery of novel rare SNVs with fast and
adequate performance. Available bioinformatics tools further allowed customized utilization of sequencing data at a
small or large scale, i.e. the assessment of individual genotypes and genes of interest or a more exhaustive pharmacogenetic analysis. Importantly, the majority of patients (78%)
harbored one or more homozygous PharmGKB Level 1A or
1B variant(s) with recommendations to adjust dose or for alternative therapies confirming recent findings from the
eMerge-PGx study comprising extensive sequencing data
from 5000 patients for 82 pharmacogenes [46]. Moreover,
60% of the observed SNVs were rare (536 variants; 2.3 per
patient) or novel (105 variants; 4.4 per 10 patients), the
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latter absent in more than 60,000 individuals [45]; a similar
frequency of 73% has been previously reported in a
whole-genome sequencing study of 231 pharmacogenes
[20]. Accordingly, a significant portion of novel variation
will likely be missed when utilizing more cost-effective,
array-based genotyping platforms such as DMET+ (1936
SNVs in 231 pharmacogenes; Affymetrix, CA, USA) or the
genome-wide Infinium Global Screening Array-24 (665,608
SNVs; Illumina, CA, USA). Moreover, the capacity of assessing CNV in pharmacogenes is an additional advantage of
this NGS panel. Overall, the multitude of other, newly discovered candidate variants among pharmacogenes in this
study highlights the need for comprehensive sequencing approaches to determine the likely more complex genotype of
a patient, while high-throughput experimental strategies are
warranted to screen and confirm effects of previously unreported genetic variation on protein activity.
While NGS is thought to be best suited for the detection
of SNV, most recent reports highlight its utility for the
identification of genomic structural variants as demonstrated for GSTs [27], the LDL receptor (LDLR) [40], the
PCSK9 enzyme (PCSK9) [47], and various genes underlying retinal dystrophies [48], among others. Our findings
demonstrate that a read-depth based approach can be successfully applied for the identification of CNV in CYP2D6,
a gene notorious for its complex genomic architecture
and pseudogene homology [30, 49]. CYP2D6 gene deletion (*5 allele) and multiplication are commonly observed
among various ethnicities (2–3% in Caucasians) [11],
resulting in reduced (or lack of) and increased enzymatic
activity, respectively. Previously, CYP2D6 CNV has been
assessed in 61 adult [33] as well as 98 pediatric patients
[50] utilizing whole-genome sequencing data, while targeted NGS pharmacogene panels have not reported such
results [27, 28]. While previous approaches evaluating
whole-genome sequences have failed to predict CYP2D6
CNV in several subjects [33, 50], we were able to confirm
concordance in all assessed patients using the bioinformatics tool VarSeq CNV caller. Accuracy of these results
is further supported by frequencies observed in this study
that are in close agreement with the literature with 3.3%
for CYP2D6 duplication (*1xN and *4xN), and 2.5% for
CYP2D6 deletion (*1/*5, *3/*5 and *4/*5). Our findings
clearly indicate that information regarding CYP2D6 genotype and CNV is critical for accurate CYP2D6 phenotype
prediction, exemplified by duplication of non-functional
alleles such as *4. Known to metabolize about 25% of
commonly prescribed drugs [51], CYP2D6 genotype is
implicated as a pharmacogenomic biomarker in drug
labelling in about 25% of medications currently listed by
the FDA (http://www.fda.gov/Drugs/ScienceResearch/
ucm572698.htm), and genotype-based prescribing guidelines have been previously published for tamoxifen [11],
codeine [52], and tricyclic antidepressants [53].
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To our knowledge, this is the first study reporting the
utility of NGS data to identify UGT1A1*28 allele status.
However, for this purpose, manual assessment of the
(TA)n repeat in sequencing reads within the UGT1A1
promoter region was required for each subject. Additional
bioinformatics tools are warranted to automate variant
calling of UGT1A1*28 to enable high-throughput analysis
in large patient numbers. UGT1A1*28 has been reported
to lower glucuronidation rate of the active metabolite of
irinotecan, SN-38, likely associated with higher toxicity
[54, 55], and is currently part of prescribing guidelines for
atazanavir [14].
A significant number of pharmacogenetic variants detected in our validation cohort was either rare or novel
(60%), and more than half (55%) resulted in amino acid
changes, supporting previous observations in larger datasets [17, 46, 56, 57]. While the proportion of SNVs with
predicted effects on protein function differed among applied in silico tools, differences in scoring have been previously observed and are not surprising given the way these
algorithms were derived [27]. SIFT leverages the evolutionary conservation of amino acids [43], PolyPhen-2 uses
pathogenicity information [44], while CADD is the most recent algorithm integrating conservation metrics, regulatory
information, and protein-level effect among others [42].
Moreover, a higher false negative rate may apply for predicting rare gain-of-function compared to loss-of-function
variants using SIFT and PolyPhen [58], while algorithms
such as CADD may be more comparable [59]. A recent
study suggests that the in silico algorithms used here predict altered enzymatic or transporter function with about
80% accuracy compared to in vitro assessment [27]. Among
207 to 275 possibly deleterious variants predicted in this
study, rare or novel SNVs were more likely to have functional effects than common or low frequency variants
(Additional file 2: Figure S6), and accounted for 41–51% of
all deleterious SNVs. These findings are similar to a recent
report evaluating NGS data from thousands of individuals
in 146 pharmacogenes, where 30 to 40% of rare variation
was predicted to be functional [17]. Moreover, we found
that nearly all patients (221 of 235) carried at least one deleterious allele (CADD score > 20) in 12 CYP genes with key
roles in drug metabolism [56, 60]; these potentially clinically relevant findings need to be followed up.
Genetic profiling using any short-fragment sequencing platform is a widely recognized challenge for NGS
of pharmacogenes [30, 61], and requires sufficient representation of mapped sequenced reads in the region of
interest to ensure accuracy. As expected, many members of the CYP, SULT and UGT gene families were reported as harboring 250-bp sequence fragments that
map to more than one place in the genome due to their
sequence similarity, with regions that are up to 100%
identical (i.e. pseudogenes) predicted of being the most
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problematic [29]. An estimated 1.8% of our 422 kb target sequence (69 exons in 19 genes) was found to be
susceptible to potential mismapping. Although our
hybridization-based enrichment strategy achieved a median read coverage above 50x for most genes (98 of
100), the results also indicate that the median or mean
value alone may not always correctly indicate evenly
sufficient read coverage across the targeted region. Specifically, for CES1 the average median per subject was
DOC ≥100x was observed, however 30.2% of its targeted bases (Exon 12–14) showed a DOC <30x indicating areas prone to higher false negative rates (Fig. 2,
Additional file 2: Figure S3); a 95–100% sequence similarity has been previously reported for CES1 exons 12–
14 [29]. Accordingly, high homology regions may benefit from longer capture probes for hybridization-based
target enrichment to ensure appropriate capture and/or
sequence read mapping. Moreover, DOC for GSTM1
were the lowest among all genes of our panel. A previous report in a Korean population sample showed individuals with GST gene deletion (GST*0) lacked
coverage when assessed with NGS, while the number of
gene copies correlated the mean number of sequenced
read depth [27]. Deletions of GSTs are also prevalent
among Europeans (MAF ~ 0.5 [62]), and we noted 57
and 17% of our study group had near zero coverage for
GSTM1 and GSTT1, respectively, likely representing
GST*0 carrier status (Additional file 2: Figure S10).
Our findings highlight the need for monitoring targeted
regions for low sequence coverage, absent data or ambiguous calls to reduce false negative or positive findings by defining test panel limitations in agreement
with current clinical laboratory standards for NGS [63].
While we show the potential application of targeted exome sequencing as a comprehensive pharmacogenetic profiling tool, there are some limitations. Validation of
concordance was limited to variants in 39 loci in 16 genes
in our relatively small, mostly Caucasian sample, in contrast
to previously reported multi-center studies that assessed
hundreds of SNVs in larger populations [27, 28] including
commercially available DNA control samples [27, 63].
However, despite the small sample size, the herein observed
variation compared well to findings from larger data sets.
Moreover, our gene panel is largely restricted to pharmacogenes of relevance to drug disposition, while a recent report
indicates the increasing relevance of drug target genes [64].
Lastly, in contrast to whole-genome sequencing, our targeted exome panel is unable to detect pharmacogenomic
variants in 3′- and 5′-untranslated as well as intronic regions that may be of relevance.

Conclusions
Next-generation sequencing platforms are starting to
impact upon many clinical fields, especially cancer and

Gulilat et al. BMC Medical Genomics

(2019) 12:81

pediatrics. Bringing these technologies to clinical pharmacogenetics represents a timely and logical convergence, especially given the history of applied genetic concepts and
molecular methods within the discipline. Through comprehensive validation of performance and accuracy, results
from our study and others demonstrate the utility of targeted exome sequencing panels as sensitive and reliable
sequencing platforms for pharmacogenes, including
CYP2D6 CNV [27, 28]. But despite the relative ease of the
sequencing process, the time and effort required for
post-sequencing computational and bioinformatics data
analyses are significant due to the technical and interpretive
complexity of NGS and the biology of some pharmacogenetic gene targets. Moreover, as new variants are discovered
using these high-throughput detection methods, the need
for standards in attributing pathogenicity together with
development of tools for high-throughput functional
assessment and clinical validation are required before implementing findings to aid therapeutic decision-making.
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